213 related articles for article (PubMed ID: 2996442)
21. [The efficacy and side effects of chemotherapy for primary lung cancer with cisplatin and etoposide].
Tsutsumi T; Kawakami A; Ozawa Y; Kawaguchi H; Fujii H; Sawano T; Asamoto H
Gan To Kagaku Ryoho; 1991 May; 18(6):1003-6. PubMed ID: 1851407
[TBL] [Abstract][Full Text] [Related]
22. [Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].
Homma T; Yoneda S; Fukuda Y; Nakata M; Noguchi Y; Yoshida S
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2399-403. PubMed ID: 3015045
[TBL] [Abstract][Full Text] [Related]
23. [A phase II study of epirubicin in advanced lung cancer].
Furuse K; Fukuoka M; Yamamoto M; Kawahara M; Tsuruta M; Kodama N; Arai R; Hayashi S; Kiyota M; Kubota K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2835-40. PubMed ID: 3019252
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of VP-16-213 in non-small-cell lung cancer.
Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
[TBL] [Abstract][Full Text] [Related]
25. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
[TBL] [Abstract][Full Text] [Related]
27. [Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
Hayasaka S; Kinuwaki E; Nakabayashi T; Saito R; Komatsu H; Nishikawa H; Ohizumi K; Shimizu T; Nakai Y; Niitani H
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec; 33(12):1367-1371. PubMed ID: 8821989
[TBL] [Abstract][Full Text] [Related]
28. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
29. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Fujita K; Murayama T; Sayama T
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
[TBL] [Abstract][Full Text] [Related]
30. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
32. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Kimura K; Yamada K; Yoshida T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
[TBL] [Abstract][Full Text] [Related]
33. [An elderly case of small cell lung cancer showing a good partial response by chronic daily administration of oral etoposide].
Ishikawa S; Shimizu E; Kawaji K; Mukai J; Tani K; Okubo A; Ogura T; Sano T; Yamashita T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):111-4. PubMed ID: 1846280
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
35. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
36. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
Eagan RT; Ingle JN; Creagan ET; Frytak S; Kvols LK; Rubin J; McMachon RT
Cancer Treat Rep; 1978 May; 62(5):843-4. PubMed ID: 657168
[No Abstract] [Full Text] [Related]
37. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary phase II study of cis-Dichlorodiammineplatinum (II) in patients with non-small cell carcinoma of the lung and metastatic pulmonary tumor].
Tominaga K; Saijo N; Eguchi K; Shinkai T; Shimizu E
Gan No Rinsho; 1984 Sep; 30(11):1344-50. PubMed ID: 6094880
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
[TBL] [Abstract][Full Text] [Related]
40. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
